Frontotemporal Dementia Market to Grow with a CAGR of 6.39% through 2030F
Increasing Frontotemporal Dementia drug development and
increasing prevalence of dementia is expected to drive the Global
Frontotemporal Dementia Market growth in the forecast period, 2026-2030.
According to TechSci Research report, “Frontotemporal Dementia Market –
Global Industry Size, Share, Trends, Opportunity, and Forecast,
2020–2030F”, the Frontotemporal Dementia Market stood at USD 241.36
Million in 2024 and is anticipated to project robust growth in the forecast
period with a CAGR of 6.39% through 2030. This is attributed to the increasing
prevalence of dementia. Dementia encompasses cognitive and communicative
dysfunction symptoms and serves as an indicator of various underlying
conditions, including brain abnormalities. The market is anticipated to expand
due to the rising prevalence of target diseases and an aging population affected
by these conditions. According to the World Health Organization,
approximately 50 million people worldwide suffer from dementia, with around 10
million new cases diagnosed annually, signifying ongoing business development.
Cognitive deficits encountered by individuals with dementia include memory
loss, confusion, behavioral changes, and planning difficulties.
Consequently, the Frontotemporal Dementia Market is expected
to exhibit growth throughout the forecast period. Market growth is further
driven by increasing awareness of frontotemporal disorders, which encompass a
range of symptoms and progressive functional and behavioral language
abnormalities. Significant investment in research and development by
governments worldwide is projected to serve as a prominent driver for the
Frontotemporal Dementia market during the forecast period. Government agencies
such as the National Institute of Aging (NIA), the National Institute of
Neurological Disorders and Strokes (NINDS), and the National Institute of
Health (NIH) provide funding for neurological disease research and development.
The market growth is being boosted by the increasing drug development grants
and funding from both government and non-government sources. Currently, there
are no FDA-approved disease-modifying treatments for frontotemporal disorders,
with symptomatic treatment providing limited benefit to patients. Recent
scientific discoveries have enhanced our understanding of the underlying
pathogenic mechanisms of frontotemporal disorders, stimulating the development
of potential disease-modifying therapies. To expedite the research and drug
development process, the Association for Frontotemporal Degeneration (AFTD) and
the Alzheimer's Drug Discovery Foundation (ADDF) jointly issued a request for
proposals (RFP) in December 2020. The aim is to advance and accelerate the
diagnosis and treatment of frontotemporal disorders, which is the most common
dementia in individuals under 60. The Treat FTD Fund provides funding for this
RFP, with award recipients eligible for up to USD 2.0 million. As a result,
this situation is expected to drive the demand for frontotemporal disorder
treatments in the forecast period.
The Global Frontotemporal Dementia Market is segmented into drug class, disease
indication, distribution channel, regional distribution, and company.
Based on distribution channel, Hospital Pharmacies was the dominant distribution channel. This is primarily due to the complex nature
of diagnosing and managing FTD, which often requires specialist care, including
neurologists, psychiatrists, and geriatricians typically based in hospital
settings. Hospital Pharmacies ensure the timely and accurate dispensing of
advanced medications used in managing cognitive and behavioral symptoms
associated with FTD. Many FTD patients are treated in specialized clinics or
memory care units, where medications are administered and monitored within
hospital environments. Hospital Pharmacies are better equipped to handle such
prescriptions, particularly for newer or off-label therapies that may not be
widely available in retail or online settings. The need for coordinated care,
frequent monitoring, and adjustments in therapy further strengthens the role of
Hospital Pharmacies. While Retail and Online Pharmacies are expanding,
particularly in developed regions, they generally serve supportive roles. Thus,
due to their infrastructure and proximity to specialized care, Hospital
Pharmacies remain dominant in the FTD market.
Based on region, the Asia-Pacific region is the
fastest-growing market in various sectors, including healthcare, due to several
key factors driving rapid expansion. One major contributor is the large and
aging population, particularly in countries like China, India, and Japan, which
is increasing the demand for healthcare services, including diagnostics,
treatment, and long-term care for chronic and neurological conditions such as
dementia. Economic growth in the region has led to rising disposable incomes,
greater healthcare awareness, and improved access to medical services.
Governments are significantly increasing healthcare investments, launching
national health insurance schemes, and encouraging public-private partnerships,
all of which are strengthening healthcare infrastructure. In addition,
technological advancements and high digital adoption are supporting the growth
of telemedicine, remote patient monitoring, and digital health tools. The
region also benefits from a large pool of healthcare professionals and growing
research activity, often supported by global collaborations. Pharmaceutical and
medical device companies are increasingly entering the Asia-Pacific market due
to lower manufacturing costs, favorable regulatory reforms, and expanding clinical
trial networks. These elements together create a fertile ground for innovation
and commercialization. The combination of demographic shifts, economic
development, policy support, and tech-driven healthcare innovation makes
Asia-Pacific the fastest-growing region across many health-related markets.
Major companies operating in Global Frontotemporal Dementia Market are:
· Transposon
Therapeutics
· Alector
Inc.
· Denali
Therapeutics Inc.
· Pfizer
Inc.
· Johnson
& Johnson Services Inc.
· Prevail
Therapeutics
· Wave
Life Sciences
· AstraZeneca
plc
· GlaxoSmithKline
plc
· TauRx
Pharmaceuticals Ltd.
Customers can also request for 10% free customization
on this report.
“The frontotemporal dementia market is driven by rising genetic mutations
affecting brain function, increasing the need for effective treatments. Growing
use of neuropsychological testing, along with the adoption of antidepressants,
antipsychotics, and non-pharmacological therapies like occupational and speech
therapy, supports market growth. R&D investments in innovative treatments,
such as gene therapy, and faster regulatory approvals are boosting market
expansion” said Mr. Karan Chechi, Research Director of TechSci Research, a
research-based management consulting firm.
“Frontotemporal Dementia Market - Global Industry Size, Share, Trends,
Opportunity, and Forecast, Segmented By Drug Class (Cognitive Enhancers,
Antipsychotics, Antidepressants, CNS Stimulants, and Other Drug Classes), By
Disease Indication (Frontotemporal Dementia, Primary Progressive Aphasia, and
Movement Disorders), By Distribution Channel (Hospital Pharmacies, Retail
Pharmacies, and Online Pharmacies), By Region and Competition,
2020-2030F”, has evaluated the future growth potential of Global
Frontotemporal Dementia Market and provides statistics & information on
market size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global
Frontotemporal Dementia Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com